Minze Health develops digital diagnostics, remote patient monitoring and Prescription Digital Therapeutics (PDTs) for urinary dysfunction and incontinence, including products such as Homeflow and Diary Pod. Its solutions have been used by over 160,000 patients and are trusted by clinicians in 20+ countries. All Minze products are CE‑marked, FDA listed and developed under GDPR and HIPAA regulations. The company plans to commercialize PDTs for lower urinary tract symptoms with initial market focus on Germany and France, leveraging DIGA and PECAN reimbursement schemes. Minze is also driving U.S. market entry for its at‑home diagnostic solutions and plans to increase utilization of Homeflow and Diary Pod in the U.S. To support U.S. commercialization it has appointed a VP Marketing & Sales and intends to establish a U.S. office and team. Minze Health builds hardware and software solutions—including explainable AI-based tools—for screening, diagnostics and remote patient monitoring of lower urinary tract symptoms (LUTS). The company reports deployment across roughly 300 hospitals, urology practices and pelvic floor rehabilitation centers worldwide. Minze frames its addressable population as 2.3 billion people with LUTS, while its CEO referenced an underserved population of approximately 1.5 billion people. Its product combines home medical devices with comprehensive software diagnostics and generates patient-level datasets to enable personalized care from lifestyle advice to digital therapeutics. Proceeds from the recent financing will fund additional clinical studies in Europe and the U.S., execution of the product roadmap, and international B2B/B2C go-to-market expansion. Minze’s stated mission is to bring LUTS diagnostics, treatment and follow-up into patients’ homes to improve accessibility and reduce healthcare costs.

Total raised

$9M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2024